CMS Open Payments · Program Year 2024
Medunik USA Inc.
Medunik USA Inc. reported $2,137.13 across General Payments, Research, and Ownership to 52 physicians and teaching hospitals across 52 transactions.
- $2.1K Below-median payer
- All-tracks total
- 52 Below-median volume
- Transactions
- 52 Below-median reach
- Recipients
- #1790
- of 1,925 companies
Medunik USA Inc. reported $2,137.13 across all CMS Open Payments tracks (General + Research + Ownership) to 52 physicians and teaching hospitals in Program Year 2024 - ranking #1790 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,137.13, averaging $41.10 per recipient.
Medunik USA Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer medunik-usa-inc Medunik USA Inc.
$2.1K · #1790/1,925 · 0.0% industry · PY2024
- TOT $2.1K
- RANK #1790
- SHARE 0.0%
- TXN 52
- RCP 52
- CAT 2
- GEN $2.1K
- TOP1 46.8%
- PY 2024
Volume peers
Nearest volume peer: Thermo Fisher Scientific Asheville LLC ($2.2K)
Medunik USA Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Medunik USA Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Medunik USA Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
49 transactions worth $1.1K make "Food and Beverage" the top general-payment category in the 2-category breakdown below, 53.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Medunik USA Inc.'s 2-category general-payment breakdown at $1.1K, 53.2% of the reported total.
How Medunik USA Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.1K | 49 | 53.2% |
| Consulting Fee | $1.0K | 3 | 46.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,172.16 (54.8%) of $2,137.13 in this company's General Payments records across 47 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Medunik USA Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Holly Bernal
$1,000.00 across 3 reported transactions
- 2
Abigail J Cruz
$49.23 across 2 reported transactions
- 3
Brandon Chalazan
$45.70 across 2 reported transactions
- 4
Tarachandra M Narumanchi
$42.03 across 2 reported transactions
- 5
Manisha M Bansal
$35.20 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Medunik USA Inc. ranks #1790 of 1,925 by total payments (bottom 7% by spend) but is notably more concentrated than that alone would suggest -- #705 of 1,838 by HHI (top 38% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Mizuho America, Inc. : $403.0K total payments, HHI 2287
- Lantheus Medical Imaging, Inc. : $1.6M total payments, HHI 2283
- Les Laboratoires Servier : $14.8K total payments, HHI 2263
- BioWound Solutions, Inc. : $24.1K total payments, HHI 2261
- Leica Microsystems (Schweiz) AG : $29.5K total payments, HHI 2261
- Cg Medtech USA, Inc : $123.9K total payments, HHI 2257
- Medunik USA Inc. (this company) : $2.1K total payments, HHI 2256
- Advanced Bionics, LLC : $64.6K total payments, HHI 2255
- Activ Surgical, Inc. : $48.3K total payments, HHI 2249
- Haemonetics Corporation : $1.2M total payments, HHI 2247
- Actelion Pharmaceuticals, Ltd : $103.2K total payments, HHI 2241
- Catalyst OrthoScience : $619.0K total payments, HHI 2229
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Medunik USA Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Medunik USA Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Medunik USA Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Vision Quest Industries Inc.
American National Red Cross
Dymicron
Picard Medical Inc.
3Shape A/S
Put this to use
Medunik USA Inc. ranks #1790 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Medunik USA Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.